The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer
acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (…

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people …

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

We compared MRI criteria used to predict conversion of suspected multiple sclerosis to
clinically definite multiple sclerosis. Seventy-four patients with clinically isolated neurological …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …

Background Interferon beta reduces activity in multiple sclerosis as measured clinically and
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …

Widespread demyelination and axonal loss are the pathological hallmarks of multiple sclerosis.
The multifocal nature of this chronic inflammatory disease of the central nervous system …